“
TL;DR
It found that traditional factors like age, stage, and tumor size were significant, while among inflammatory indices, only a higher systemic immune inflammation index was linked to worse distant metastasis-free survival.
Journal of Personalized Medicine · 18 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It found that traditional factors like age, stage, and tumor size were significant, while among inflammatory indices, only a higher systemic immune inflammation index was linked to worse distant metastasis-free survival.
Pretreatment values of ten inflammatory indices were analyzed alongside clinical factors for correlations with survival outcomes. At multivariable analysis, older age, advanced FIGO stage, lower hemoglobin, larger tumor size, and higher BMI were significantly correlated with clinical outcomes. Among all inflammatory indices analyzed, only a higher systemic immune inflammation index (SII) was significantly associated with lower distant metastasis-free survival (p < 0.01). No significant correlation was found between any inflammatory index and disease-free survival or overall survival. The study limitations include a relatively small sample for subgroup analyses, unavailable data for some known factors like SCC antigen, and the use of continuous rather than cut-off values for indices.